semaglutide bimagrumab plus alone or in combination for the treatment of obesity: a randomized phase 2 trial Eli Lilly's Next-Gen Obesity Therapies:

What GLP-1 Medications Actually Do GLP-1 (glucagon-like peptide-1) receptor agonists work by: Slowing gastric emptying Reducing appetite and food intake Improving glucose control Enhancing insulin response These effects are extremely effective for reducing caloric intake , which explains the dramatic short-term weight loss many patients see

It is not addictive and does not have serious or long term side effects

Despite how these products are promoted, presented and packaged, consumers have no way of knowing whether they are authorised medicines or if they have been subjected to any safety or quality assessments

Contains lactose